Advertisement

Topics

Catalent’s $1.2bn Paragon deal sign of booming gene therapy market

13:12 EDT 16 Apr 2019 | BioPharma-Reporter

Catalent to acquire Paragon and plans âsubstantial capital investmentsâ to ensure Paragonâs further growth, the latest deal in a busy area.

Original Article: Catalent’s $1.2bn Paragon deal sign of booming gene therapy market

NEXT ARTICLE

More From BioPortfolio on "Catalent’s $1.2bn Paragon deal sign of booming gene therapy market"

Advertisement
Quick Search
Advertisement
Advertisement